Galapagos NV ADR (GLPG)vsMerck & Company Inc (MRK)
GLPG
Galapagos NV ADR
$27.86
-1.97%
HEALTHCARE · Cap: $1.91B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 5745% more annual revenue ($65.01B vs $1.11B). GLPG leads profitability with a 28.8% profit margin vs 28.1%. GLPG trades at a lower P/E of 5.0x. GLPG earns a higher WallStSmart Score of 74/100 (B).
GLPG
Strong Buy74
out of 100
Grade: B
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.3%
Fair Value
$316.70
Current Price
$27.86
$288.84 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Strong operational efficiency at 88.0%
Revenue surging 1093.0% year-over-year
Earnings expanding 3036.0% YoY
Keeps 29 of every $100 in revenue as profit
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Trading at 9.6x book value
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : GLPG
The strongest argument for GLPG centers on P/E Ratio, Operating Margin, Revenue Growth. Profitability is solid with margins at 28.8% and operating margin at 88.0%. Revenue growth of 1093.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : GLPG
The primary concerns for GLPG are Price/Book, Market Cap, Free Cash Flow.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
GLPG profiles as a growth stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
GLPG is growing revenue faster at 1093.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
GLPG scores higher overall (74/100 vs 59/100), backed by strong 28.8% margins and 1093.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Galapagos NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?